Philadelphia, PA, April 29, 2009 – Relationships are difficult and most of us probably think at some point that communicating positively with our partner when discussing stressful issues, like home finances, is an impossible task. What if there was a safe way to take the "edge" off these discussions? The biology of human social relationships is just beginning to emerge as groundbreaking research on social cognition conducted in animals is now informing research in humans.
In its May 1st issue, Biological Psychiatry (http://www.elsevier.com/locate/biopsychiat), published by Elsevier, includes a paper by Swiss researchers that have investigated the effects of oxytocin, the "love hormone," on human couple interactions. They recruited adult couples who received oxytocin or placebo intranasally before engaging in a conflict discussion in the laboratory. Oxytocin increased positive communication behavior in relation to negative behavior and reduced salivary cortisol, i.e., their stress levels, compared to placebo.
"We are just beginning to understand the powerful effects of hormones and chemicals released by the body in the context of important social interactions," commented John Krystal, M.D., the editor of Biological Psychiatry. "As this knowledge grows, the question of how to best use our developing capacities to pharmacologically alter social processes will become an important question to explore."
Author Beate Ditzen, Ph.D., noted that this was the first study of its kind and important because it evaluated real-time natural couple behavior in the laboratory. "[Oxytocin] might help us to pronounce the effects of a standard treatment, such as cognitive behavioral therapy, by possibly making the benefits of social interaction more accessible to the individual. But it probably will not replace these standard treatments."
They clarify that this study does not show that oxytocin should currently be used as a treatment itself and the effects of repeated administration have not been evaluated in humans. In addition, important ethical concerns will have to be addressed, such as to what extent it should be used as a "treatment" and whether developed treatments could become drugs of abuse in the form of "social enhancers."
Notes to Editors:
The article is "Intranasal Oxytocin Increases Positive Communication and Reduces Cortisol Levels During Couple Conflict" by Beate Ditzen, Marcel Schaer, Barbara Gabriel, Guy Bodenmann, Ulrike Ehlert, and Markus Heinrichs. Authors Ditzen and Ehlert are affiliated with the Department of Psychology, Clinical Psychology and Psychotherapy, University of Zurich, Zurich, Switzerland. Ditzen is also with the Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia. Schaer, Gabriel, and Bodenmann are from the Department of Psychology, Institute for Family Research and Counseling, University of Fribourg, Fribourg, Switzerland. Heinrichs is affiliated with the Department of Psychology, Clinical Psychology and Psychobiology, University of Zurich, Zurich, Switzerland. The article appears in Biological Psychiatry, Volume 65, Issue 9 (May 1, 2009), published by Elsevier.
The authors' disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D. is affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System and his disclosures of financial and conflicts of interests are available at http://journals.elsevierhealth.com/webfiles/images/journals/bps/Biological_Psychiatry_Editorial_Disclosures_08_01_08.pdf.
Full text of the article mentioned above is available upon request. Contact Jayne M. Dawkins at ja.dawkins@elsevier.com to obtain a copy or to schedule an interview.
About Biological Psychiatry
This international rapid-publication journal is the official journal of the Society of Biological Psychiatry. It covers a broad range of topics in psychiatric neuroscience and therapeutics. Both basic and clinical contributions are encouraged from all disciplines and research areas relevant to the pathophysiology and treatment of major neuropsychiatric disorders. Full-length and Brief Reports of novel results, Commentaries, Case Studies of unusual significance, and Correspondence and Comments judged to be of high impact to the field are published, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Concise Reviews and Editorials that focus on topics of current research and interest are also published rapidly.
Biological Psychiatry (www.sobp.org/journal) is ranked 4th out of the 95 Psychiatry titles and 16th out of 199 Neurosciences titles on the 2006 ISI Journal Citations Reports® published by Thomson Scientific.
About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (http://www.sciencedirect.com/), MD Consult (http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/), bibliographic databases, and online reference works.
Elsevier (http://www.elsevier.com/) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Journal
Biological Psychiatry